Quantum BioPharma Ltd. (QNTM) News
Follow Quantum BioPharma Ltd. (QNTM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Quantum BioPharma Ltd. (QNTM) Licensee Unbuzzd Names Michael Zapolin CEO
Quantum BioPharma said its licensee Unbuzzd Wellness appointed Michael “Zappy” Zapolin as CEO, with a mandate to seek financing, pursue a stock exchange listing, and lead a U.S. rollout.Material DetailsContext by AI Anal
EQUITY | Sep 24, 2026, 12:03 PM UTC
L
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. NASDAQ:QNTM FRA:0K91 (“Quantum BioPharma”), today announced its licensee — Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd
NEWS | Sep 24, 2026, 12:03 PM UTC
L
QNTM - Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
QNTM - Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
NEWS | Sep 17, 2026, 12:00 PM UTC
L
QNTM - Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
QNTM - Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
NEWS | Sep 15, 2026, 12:01 PM UTC
L
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
Toronto, Ontario--(. - September 15, 2026) - Quantum BioPharma Ltd. NASDAQ:QNTM (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and b
NEWS | Sep 15, 2026, 12:01 PM UTC
L
QNTM receives FDA clearance to begin MS treatment trials
Quantum BioPharma Ltd. (NASDAQ: QNTM) received FDA clearance to begin trials for its MS treatment.
REGULATION | Sep 09, 2026, 12:30 PM UTC
L
Quantum Biopharma plans voluntary delisting of Class B shares in Canada
Quantum Biopharma said it plans to voluntarily delist its Class B shares from the Canadian Securities Exchange.
EQUITY | Sep 01, 2026, 11:02 PM UTC
L
Quantum BioPharma initiated at Buy by Rodman & Renshaw
Rodman & Renshaw initiated coverage on Quantum BioPharma with a Buy rating.
EQUITY | Aug 31, 2026, 05:11 PM UTC
M
QNTM equity, liquidity strengthened as FDA approves Lucid-MS trial
Quantum BioPharma says it strengthens equity and liquidity in Q2 2026 following FDA approval of Lucid-MS for a pivotal Phase 2 clinical trial.
EQUITY | Aug 14, 2026, 11:00 AM UTC
M
QNTM Advances MS Therapy
Quantum BioPharma Ltd. is advancing an innovative, first-in-class, patented MS therapy
EQUITY | Jun 25, 2026, 12:30 PM UTC
M
QNTM Developing MS Treatment
Quantum BioPharma Ltd. is developing a patented, first-in-class MS treatment that offers a different approach
EQUITY | Jun 23, 2026, 12:31 PM UTC